Reach-through claims for drug target patents: Rx for pharmaceutical policy.

Suppr

超能文献

作者信息

Bohrer Robert A

机构信息

California Western School of Law, 225 Cedar Street, San Diego, California 92101, USA.

出版信息

Nat Biotechnol. 2008 Jan;26(1):55-6. doi: 10.1038/nbt0108-55.

DOI:10.1038/nbt0108-55

PMID:18183015

Abstract

摘要

相似文献

Reach-through claims for drug target patents: Rx for pharmaceutical policy.

Nat Biotechnol. 2008 Jan;26(1):55-6. doi: 10.1038/nbt0108-55.

US policy may encourage counterfeit drugs.

Nat Biotechnol. 2003 Feb;21(2):121. doi: 10.1038/nbt0203-119.

The challenge to patent law of pure chemical protein synthesis.

Nat Biotechnol. 2005 May;23(5):547-9. doi: 10.1038/nbt0505-547.

Should the patent system for new medicines be abolished?

Clin Pharmacol Ther. 2007 Nov;82(5):488-90. doi: 10.1038/sj.clpt.6100393.

Using market-exclusivity incentives to promote pharmaceutical innovation.

N Engl J Med. 2010 Nov 4;363(19):1855-62. doi: 10.1056/NEJMhle1002961.

Patents: a threat to innovation?

Science. 2010 Jan 1;327(5961):31-2; author reply 32. doi: 10.1126/science.327.5961.31.

Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.

Nat Biotechnol. 2007 Oct;25(10):1105-6. doi: 10.1038/nbt1007-1105.

Patent watch: EPO rejects reach through claims.

Nat Rev Drug Discov. 2010 Jan;9(1):12. doi: 10.1038/nrd3077.

Biotech patents-business as usual?

Nat Biotechnol. 2008 Dec;26(12):1326. doi: 10.1038/nbt1208-1326.

Realizing two-tiered innovation policy through drug regulation.

Stanford Law Rev. 2006 Feb;58(4):1221-50.

引用本文的文献

Improving target assessment in biomedical research: the GOT-IT recommendations.

Nat Rev Drug Discov. 2021 Jan;20(1):64-81. doi: 10.1038/s41573-020-0087-3. Epub 2020 Nov 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Reach-through claims for drug target patents: Rx for pharmaceutical policy.

Nat Biotechnol. 2008 Jan;26(1):55-6. doi: 10.1038/nbt0108-55.

US policy may encourage counterfeit drugs.

Nat Biotechnol. 2003 Feb;21(2):121. doi: 10.1038/nbt0203-119.

The challenge to patent law of pure chemical protein synthesis.

Nat Biotechnol. 2005 May;23(5):547-9. doi: 10.1038/nbt0505-547.

Should the patent system for new medicines be abolished?

Clin Pharmacol Ther. 2007 Nov;82(5):488-90. doi: 10.1038/sj.clpt.6100393.

Using market-exclusivity incentives to promote pharmaceutical innovation.

N Engl J Med. 2010 Nov 4;363(19):1855-62. doi: 10.1056/NEJMhle1002961.

Patents: a threat to innovation?

Science. 2010 Jan 1;327(5961):31-2; author reply 32. doi: 10.1126/science.327.5961.31.

Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.

Nat Biotechnol. 2007 Oct;25(10):1105-6. doi: 10.1038/nbt1007-1105.

Patent watch: EPO rejects reach through claims.

Nat Rev Drug Discov. 2010 Jan;9(1):12. doi: 10.1038/nrd3077.

Biotech patents-business as usual?

Nat Biotechnol. 2008 Dec;26(12):1326. doi: 10.1038/nbt1208-1326.

Realizing two-tiered innovation policy through drug regulation.

Stanford Law Rev. 2006 Feb;58(4):1221-50.

引用本文的文献

Improving target assessment in biomedical research: the GOT-IT recommendations.

Nat Rev Drug Discov. 2021 Jan;20(1):64-81. doi: 10.1038/s41573-020-0087-3. Epub 2020 Nov 16.